Results 211 to 220 of about 22,731 (252)

Virologic suppression in treatment-experienced patients after virologic rebound or failure of therapy

Current Opinion in HIV and AIDS, 2011
To discuss factors related to virologic failure and review data from recent clinical trials evaluating re-suppression of viremia in extensively-treated HIV-infected patients with resistance.Factors associated with virologic failure can be related to the virus (e.g. resistance), the patient (e.g. adherence) or HIV therapy (e.g. availability) and must be
Rui, Sarmento-Castro, Carlos, Vasconcelos, Maria João, Aguas, Rui, Marques, Joaquim, Oliveira   +4 more
openaire   +2 more sources

Evaluation and management of early virological failure

Current Opinion in HIV and AIDS, 2006
To describe the causes, evaluation, and management of early virological failure in patients treated with their first antiretroviral regimen.Combination antiretroviral therapy predictably induces a rapid virological response, with the majority of patients achieving an undetectable HIV-RNA load by week 24.
openaire   +2 more sources

Early Virological Failure with a Combination of Tenofovir, Didanosine and Efavirenz

Antiviral Therapy, 2005
Objective To describe the occurrence of a high early virological failure (VF) rate and development of resistance mutations in antiretroviral-naive patients receiving tenofovir, didanosine and efavirenz.
Daniel, Podzamczer, Elena, Ferrer, Josep Maria, Gatell, Jordi, Niubo, David, Dalmau, Agathe, Leon, Hernando, Knobel, Carolina, Polo, Daniel, Iniguez, Isaac, Ruiz   +9 more
openaire   +2 more sources

Virological patterns of HCV patients with failure to interferon‐free regimens

Journal of Medical Virology, 2018
The study characterized the virological patterns and the resistance‐associated substitutions (RASs) in patients with failure to IFN‐free regimens enrolled in the real‐life setting. All 87 consecutive HCV patients with failed IFN‐free regimens, observed at the laboratory of the University of Campania, were enrolled.
Starace M, Minichini C, De Pascalis S, Macera M, Occhiello L, Messina V, Sangiovanni V, Adinolfi LE, Claar E, Precone D, Stornaiuolo G, Stanzione M, Ascione T, Caroprese M, Zampino R, Parrilli G, Gentile I, Brancaccio G, Iovinella V, Martini S, Masarone M, Fontanella L, Masiello A, Sagnelli E, Punzi R, Salomone Megna A, Santoro R, Gaeta GB, Coppola N., Stornaiuolo G, Zampino R. Parrilli G, Masarone M.   +31 more
openaire   +5 more sources

Virologic Outcome and Predictors of Virologic Failure of Highly Active Antiretroviral Therapy Containing Protease Inhibitors

AIDS Patient Care and STDs, 2001
In this observational single-center cohort study outside the clinical trial setting, outcome and predictors of virologic failure of highly active antiretroviral therapy (HAART) containing a protease inhibitor were evaluated in human immunodeficiency (HIV)-infected persons.
H, Knobel, A, Guelar, A, Carmona, M, Espona, A, González, J L, López-Colomés, P, Saballs, J L, Gimeno, A, Díez   +8 more
openaire   +2 more sources

PROTEASE INHIBITOR RESISTANCE IN SOUTH AFRICAN CHILDREN WITH VIROLOGIC FAILURE

Pediatric Infectious Disease Journal, 2009
In South Africa, first-line antiretroviral therapy for children younger than 3 years of age combines a protease inhibitor (PI) with 2 nucleoside reverse transcription inhibitors. In our study, some pediatric patients received ritonavir (RTV) as single PI (RTV-sPI) and others ritonavir-boosted lopinavir (LPV/r), which has a higher resistance barrier. We
Van Zyl G.U., Van Der Merwe L., Claassen M., Cotton M.F., Rabie H., Prozesky H.W., Preiser W.   +6 more
openaire   +3 more sources

Tackling virological failure in HIV-infected children living in Africa

Expert Review of Anti-infective Therapy, 2015
Drug resistance in HIV-infected children is one of the main contributors to antiretroviral treatment (ART) failure, especially in developing countries. Sub-Saharan Africa has the largest burden of pediatric HIV infection in the world. Herein, we systematically review the current status of ART failure in HIV-infected African children.
Mohammad-Ali, Jenabian, Cecilia T, Costiniuk, Ralph-Sydney, Mboumba Bouassa, Linda, Chapdeleine Mekue Mouafo, Thomas V, Brogan, Laurent, Bélec   +5 more
openaire   +2 more sources

Virological failure and subsequent resistance profiles in individuals exposed to atazanavir

AIDS, 2007
Few data exist regarding the resistance profile in individuals receiving atazanavir. We found that ritonavir-boosted atazanavir is not associated with the development of primary genotypic resistance in individuals failing this combination, without previous protease inhibitor failure.
Justin, Stebbing, Bif, Nathan, Rachael, Jones, Alex, McKenna, Tom, Powles, Mark, Bower, Paul, Holmes, Brian, Gazzard, Mark, Nelson   +8 more
openaire   +2 more sources

Virologic Failure of High-Dose Raltegravir With Concomitant Rifampin

Infectious Diseases in Clinical Practice, 2017
Abstract Treating mycobacterial infections and HIV concurrently typically presents difficulties due to drug-to-drug interactions between rifampin and many antiretrovirals. We present a case of raltegravir failure during concomitant rifampin use, despite documented administration of recommended increased dose of raltegravir.
Misty M. Miller, Karen K. Kinney, Michelle D. Liedtke   +2 more
openaire   +1 more source

Low-level viremia linked to virological failure but not clinical events

AIDS
Introduction: The main objective of antiretroviral therapy (ART) for people with HIV (PWH) is to maintain an undetectable viral load. This study evaluates the association between low-level viremia (LLV) (50–200 copies/ml) and virological failure, AIDS, and severe non-AIDS events, as well as the impact of sociodemographic and ...
Bernal E, Martinez-Rodriguez R, Gomez J, Tomas C, Garcia-Villalba E, Valero S, Munoz A, Alcaraz A, Diez C, Garcia-Fraile L, Gomez-Garcia T, Navarro-Marcotegui M, Aleman-Valls M, Olalla J, Masia M, Gutierrez F   +15 more
openaire   +3 more sources